

Perimed Inc, a Global Leader in the Field of Peripheral Vascular Diagnosis, Awarded Agreement with Premier Inc.

LAS VEGAS – NOVEMBER 15, 2022 – Perimed Inc has been awarded a group purchasing agreement with Premier Inc effective September 1st, 2022. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the PeriFlux 6000 and its disposables. The PeriFlux 6000 is a state-of-the-art system for quick and accurate assessment of patients suffering from peripheral vascular disease.

Vascular disease is one of the world's fastest growing health issues and is often associated with diabetic foot ulcers. At least 15% of the diabetic population will develop a foot ulcer in their lifetime. By not properly evaluating the vascular problem, the risk of the non-healing wound leading to amputation is highly increased. Currently, 14-24% of the ulcer patients require an amputation. The estimated annual direct cost of diabetic foot ulcers in the US is at least \$17 billion which is higher than the costliest cancers, such as breast cancer and colorectal cancer.

Our clinical tools provide a complete combination of vascular tests, securing accurate diagnosis of patients with peripheral arterial disease. The PeriFlux 6000 System is the only device that can perform all the non-invasive vascular measurements recommended by the Global Vascular Guidelines in one visit.

"The collaboration with Premier is a fantastic milestone for Perimed and one of the most important agreements we have entered into to date. Our vision is to save limbs, lives and human suffering. This strategic agreement enables us to rapidly expand our footprint in the US, making our state-of-the-art technology even more easily accessible to customers", says Lena Åredal, CEO at Perimed.

Premier is a leading healthcare improvement company, uniting an alliance of more than 4,400 US hospitals and approximately 250,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.

REFERENCES

1. Conte et al. *Global Vascular Guidelines 2019*
2. David Armstrong et al; *Diabetic Foot Ulcers, Prevention, Diagnosis and Classification*
3. Oliver TI et al, *Diabetic Foot: Facts and Figures*

Contacts

Lena Åredal, CEO Perimed AB
+46 (0) 72 – 4013179
lena.aredal@perimed-instruments.com

Samuel Pakvis, President Perimed Inc
+1 (805) 794-4621
spakvis@perimed-instruments.com

About Us

Perimed is a private Swedish company active on the global market, with seven subsidiaries and more than twenty distributors around the world. We have more than 40 years of experience and unique competence in laser-based blood perfusion measurements, making Perimed a leader in peripheral vascular diagnosis. Our equipment is typically used in Wound Care Departments, Diabetic Foot Clinics, Vascular Surgery/Labs and Radiology. We have over 4000 installed instruments worldwide.

Image Attachments

[US Cost Foot Ulcers](#)

Attachments

[Perimed Inc, a Global Leader in the Field of Peripheral Vascular Diagnosis, Awarded Agreement with Premier Inc.](#)